期刊
TRENDS IN MOLECULAR MEDICINE
卷 27, 期 8, 页码 731-742出版社
CELL PRESS
DOI: 10.1016/j.molmed.2020.11.009
关键词
-
PGT-A, a routine add-on for IVF, has not been clinically validated in determining human embryo chromosomal status and may actually reduce live birth chances for many patients. Recent studies have shown the PGT-A hypothesis to be mistaken.
Preimplantation genetic testing for aneuploidy (PGT-A) has become a routine add-on for in vitro fertilization (IVF) to determine whether human embryos are to be clinically utilized or disposed of. Studies claiming IVF outcome improvements following PGT-A, however, used highly selected patient populations or inappropriate statistical methodologies. PGT-A was never clinically validated in its ability to define a human embryo as chromosomal normal, mosaic, or aneuploid, nor certified by a regulatory body, or an authoritative professional organization. Because of a high false-positive rate, PGT-A, actually reduces live IVF birth chances for many patients. Furthermore, in recent studies the PGT-A hypothesis was demonstrated to be mistaken for biological, mathematical and technical reasons. PGT-A, therefore, should clinically only be offered within experimental study frameworks.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据